[go: up one dir, main page]

BR9806568A - Forma de cristal de n-(4-trifluormetilfenil)-5-metilisoxazol-4-carboxamida - Google Patents

Forma de cristal de n-(4-trifluormetilfenil)-5-metilisoxazol-4-carboxamida

Info

Publication number
BR9806568A
BR9806568A BR9806568-8A BR9806568A BR9806568A BR 9806568 A BR9806568 A BR 9806568A BR 9806568 A BR9806568 A BR 9806568A BR 9806568 A BR9806568 A BR 9806568A
Authority
BR
Brazil
Prior art keywords
carboxamide
crystal form
trifluormethylphenyl
methylisoxazole
crystal
Prior art date
Application number
BR9806568-8A
Other languages
English (en)
Inventor
Holger Dr Faasch
Udo Dr Hedtmann
Uwe Dr Westenfelder
Erich Dr Paulus
Original Assignee
Hoechst Marion Roussel De Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19734438A external-priority patent/DE19734438A1/de
Priority claimed from DE1997156093 external-priority patent/DE19756093A1/de
Application filed by Hoechst Marion Roussel De Gmbh filed Critical Hoechst Marion Roussel De Gmbh
Publication of BR9806568A publication Critical patent/BR9806568A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Patente de Invenção: <B>"FORMA DE CRISTAL DE N-(4-TRIFLUORMETIL-FENIL)-5-METILISOXAZOL-4-CARBOXAMIDA"<D>. A invenção refere-se à Modificação 2 do cristal do composto de fórmula I processos para a preparação das Modificações de cristal 1 e 2 e ao uso das mesmas.
BR9806568-8A 1997-08-08 1998-08-07 Forma de cristal de n-(4-trifluormetilfenil)-5-metilisoxazol-4-carboxamida BR9806568A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19734438A DE19734438A1 (de) 1997-08-08 1997-08-08 Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid
DE1997156093 DE19756093A1 (de) 1997-12-17 1997-12-17 Verfahren zur Herstellung einer Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid

Publications (1)

Publication Number Publication Date
BR9806568A true BR9806568A (pt) 2000-05-16

Family

ID=26038983

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9806568-8A BR9806568A (pt) 1997-08-08 1998-08-07 Forma de cristal de n-(4-trifluormetilfenil)-5-metilisoxazol-4-carboxamida

Country Status (28)

Country Link
US (5) US6060494A (pt)
EP (2) EP0903345B1 (pt)
JP (2) JPH11124372A (pt)
KR (2) KR100544041B1 (pt)
CN (2) CN1089759C (pt)
AR (1) AR015418A1 (pt)
AT (2) ATE207065T1 (pt)
AU (1) AU752764B2 (pt)
BR (1) BR9806568A (pt)
CA (1) CA2245267C (pt)
CZ (3) CZ292943B6 (pt)
DE (2) DE59801792D1 (pt)
DK (2) DK0903345T3 (pt)
ES (2) ES2166205T3 (pt)
GR (1) GR3034814T3 (pt)
HK (2) HK1017681A1 (pt)
HU (2) HU229232B1 (pt)
ID (1) ID20667A (pt)
IL (1) IL125671A (pt)
NO (1) NO310871B1 (pt)
NZ (1) NZ331270A (pt)
PL (1) PL192126B1 (pt)
PT (2) PT903345E (pt)
RU (1) RU2224753C2 (pt)
SK (2) SK285216B6 (pt)
TR (2) TR200600582A1 (pt)
TW (1) TW593288B (pt)
UA (1) UA54411C2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903345B1 (de) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
DE19908527C2 (de) 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
AU779931B2 (en) * 1999-12-16 2005-02-17 Teva Pharmaceutical Industries Ltd. Novel processes for making- and a new crystalline form of- leflunomide
ES2237553T3 (es) * 2000-02-15 2005-08-01 Teva Pharmaceutical Industries Ltd. Procedimiento para la sintesis de leflunomida.
WO2002040458A1 (fr) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Derives d'isoxazole
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
WO2003068239A1 (fr) * 2002-02-12 2003-08-21 Sumitomo Pharmaceuticals Co., Ltd. Nouveaux medicaments d'usage externe
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
ES2232332T3 (es) * 2003-03-12 2007-08-16 Teva Pharmaceutical Industries Ltd Composiciones farmaceuticas estables de desloratadina.
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
JP4223428B2 (ja) * 2004-03-31 2009-02-12 富士通メディアデバイス株式会社 フィルタおよびその製造方法
WO2007067710A1 (en) * 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
CN101143834B (zh) * 2006-09-15 2010-09-08 欣凯医药化工中间体（上海）有限公司 N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法
UY31695A (es) * 2008-03-10 2009-11-10 Takeda Pharmaceutical Cristal de compuestos de bencimidazol
CN104666238B (zh) 2009-09-18 2018-04-06 赛诺菲 稳定性提高的(z)‑2‑氰基‑3‑羟基‑丁‑2‑烯酸‑(4’‑三氟甲基苯基)‑酰胺片剂制剂
CN103977594B (zh) * 2014-06-03 2016-02-17 江苏九九久科技股份有限公司 一种结晶方法
US9895370B2 (en) * 2015-11-19 2018-02-20 Pharmedix.Co., Ltd Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising G protein coupled receptor 119 ligand as an active ingredient
CN109180599A (zh) * 2018-09-03 2019-01-11 深圳市新阳唯康科技有限公司 一种来氟米特新晶型化合物及其制备方法
CN112898215B (zh) * 2021-02-04 2022-11-08 美罗药业股份有限公司 一种来氟米特晶型i的制备方法
CN114716388B (zh) * 2021-11-04 2024-02-13 江苏冠军科技集团股份有限公司 一种磺胺-银化合物及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
ES448386A1 (es) * 1975-06-05 1978-04-16 Hoechst Ag Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
DE2525959A1 (de) * 1975-06-11 1977-02-10 Focke Pfuhl Verpack Automat Verpackung fuer zigaretten, zigarillos etc.
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4935434A (en) * 1988-01-26 1990-06-19 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
DK0527736T3 (da) * 1990-05-18 1997-10-20 Hoechst Ag Isoxazol-4-carboxylsyreamider og hydroxyalkyliden-cyanoacetamider, lægemidler indeholdende disse forbindelser og anvendelsen af disse lægemidler.
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
GB9209330D0 (en) * 1992-04-30 1992-06-17 Roussel Lab Ltd Chemical compounds
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
ATE174219T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha
ATE174220T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von interleukin 8
TW314467B (pt) * 1993-03-31 1997-09-01 Hoechst Ag
GB9320299D0 (en) * 1993-10-01 1993-11-17 Roussel Lab Ltd Isoxazole derivatives
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
ATE194912T1 (de) * 1994-10-17 2000-08-15 Aventis Pharma Ltd Mittel zur vorsorge und heilung von typ i allergischen krankheiten
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6316479B1 (en) * 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
HRP980291A2 (en) * 1997-06-16 1999-04-30 Lin-Hua Zhang Crystalline roxifiban
EP0903345B1 (de) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
US6096770A (en) * 1998-08-03 2000-08-01 American Home Products Corporation Anthranilic acid analogs
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
AU779931B2 (en) * 1999-12-16 2005-02-17 Teva Pharmaceutical Industries Ltd. Novel processes for making- and a new crystalline form of- leflunomide
ES2237553T3 (es) * 2000-02-15 2005-08-01 Teva Pharmaceutical Industries Ltd. Procedimiento para la sintesis de leflunomida.
US6727272B1 (en) * 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis

Also Published As

Publication number Publication date
HK1049481B (zh) 2005-07-08
UA54411C2 (uk) 2003-03-17
SK105898A3 (en) 1999-02-11
HUP9801844A2 (hu) 2000-02-28
HU225870B1 (en) 2007-11-28
CA2245267C (en) 2008-12-23
TW593288B (en) 2004-06-21
CZ301514B6 (cs) 2010-03-31
DE59801792D1 (de) 2001-11-22
PL327901A1 (en) 1999-02-15
HU229232B1 (en) 2013-09-30
US6552202B2 (en) 2003-04-22
CN1373126A (zh) 2002-10-09
JP2009280604A (ja) 2009-12-03
TR199801513A2 (xx) 1999-02-22
US6221891B1 (en) 2001-04-24
JPH11124372A (ja) 1999-05-11
US6060494A (en) 2000-05-09
CN1089759C (zh) 2002-08-28
TR199801513A3 (tr) 1999-02-22
US6900334B2 (en) 2005-05-31
CZ301426B6 (cs) 2010-02-24
IL125671A (en) 2002-11-10
US20030166945A1 (en) 2003-09-04
KR100588254B1 (ko) 2006-06-12
CN1208034A (zh) 1999-02-17
CA2245267A1 (en) 1999-02-08
ES2166205T3 (es) 2002-04-01
US20030027851A1 (en) 2003-02-06
CN1181064C (zh) 2004-12-22
ID20667A (id) 1999-02-11
EP0987256A1 (de) 2000-03-22
DE59800287D1 (de) 2000-11-09
CZ292943B6 (cs) 2004-01-14
HK1017681A1 (en) 1999-11-26
IL125671A0 (en) 1999-04-11
AU7887098A (en) 1999-02-18
PT987256E (pt) 2002-03-28
ATE196764T1 (de) 2000-10-15
DK0903345T3 (da) 2000-10-23
PL192126B1 (pl) 2006-09-29
NO983632D0 (no) 1998-08-07
US6995272B2 (en) 2006-02-07
RU2224753C2 (ru) 2004-02-27
KR20050077498A (ko) 2005-08-02
HU9801844D0 (en) 1998-10-28
CZ246898A3 (cs) 1999-02-17
AU752764B2 (en) 2002-09-26
NO983632L (no) 1999-02-09
SK285216B6 (sk) 2006-09-07
TR200600582A1 (tr) 2006-08-21
ES2150808T3 (es) 2000-12-01
EP0903345A1 (de) 1999-03-24
DK0987256T3 (da) 2002-02-11
AR015418A1 (es) 2001-05-02
NO310871B1 (no) 2001-09-10
EP0903345B1 (de) 2000-10-04
PT903345E (pt) 2001-01-31
HU0700190D0 (en) 2007-05-02
HK1049481A1 (en) 2003-05-16
GR3034814T3 (en) 2001-02-28
HUP9801844A3 (en) 2000-04-28
KR100544041B1 (ko) 2006-09-18
EP0987256B1 (de) 2001-10-17
ATE207065T1 (de) 2001-11-15
NZ331270A (en) 2000-04-28
US20040204465A1 (en) 2004-10-14
KR19990023433A (ko) 1999-03-25
SK282641B6 (sk) 2002-10-08

Similar Documents

Publication Publication Date Title
BR9806568A (pt) Forma de cristal de n-(4-trifluormetilfenil)-5-metilisoxazol-4-carboxamida
BR0111913A (pt) Análogos de gabapentina para distúrbios do sono
ES263908Y (es) &#34;bloque perfeccionado para la construccion de edificios&#34;.
BR0014293A (pt) Uso de retigabina para o tratamento de dor neuropática
DK0804421T3 (da) 2-((Dihydro)pyrazolyl-3&#39;-oxymethylen)-anilider som skadedyrsbekæmpelsesmidler og fungicider
BR9711194A (pt) Uso de agente quelante clioquinol para a fabricação de uma composição farmacêutica para o tratamento de doença de alzheimer.
PT1100459E (pt) Preparacao oleosa espumante e sua utilizacao
BR9709062A (pt) Composto, composição farmacêutica, e, uso de um composto.
PA8506301A1 (es) Cristal de 4- carboxamino- 1,2,3,4,- tetrahidroquinolina 2-sustituida
FR10C0001I2 (fr) Benzamide peristaltique
NO971789D0 (no) Di-tert-butylfenolforbindelser med heterocyklisk enhet for anvendelse som antiinflammatoriske midler
DK1007024T3 (da) Doseringsformer af sertralin med forsinket frigivelse
DK0941097T3 (da) Anvendelse af aktivstofblandinger til fremstilling af hypocholesterolæmiske midler
ES494426A0 (es) Procedimiento para la preparacion de n- (trimetoxibencil)- n&#39;-fenilpiperazinas
BR9814495A (pt) Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo
DE60121048D1 (de) PYRAZINOi1&#39;2&#39;:1,6öPYRIDOi3,4-BöINDOLDERIVATE
BR0016941A (pt) Derivados de aminometil-fenil-ciclohexanona
IT8922246A0 (it) Procedimento di preparazione di 3-ciano-3,5,5&#39;-trimetil-1-cicloesanone
ES532125A0 (es) Un procedimiento de preparacion de nuevas formas galenicas de n-(etil-1-pirrolidinil-2-)-metil-metoxi-2-sulfamoil-5-benzamida, utilizables por via oral
BR9809439A (pt) Processos para preparação de benzotiofenos
DK158729C (da) N-(3-trifluormethylphenyl)-n&#39;-propargylpiperazin, farmaceutiske praeparater, der indeholder det, dets anvendelse, samt en fremgangsmaade til fremstilling af et farmaceutisk praeparat
BR9810387A (pt) (s) 3, 4, 5-trimetoxibenzoato de 2-metilamino-2-fenil-n-butila, e sua aplicação para o tratamento de dor crÈnica
ES516319A0 (es) &#34;procedimiento para la preparacion de n-(3-trimetilestannilalquilen)-n&#39;-fenilsulfonil y respectivamente-benzoil-ureas&#34;.
BR9809286A (pt) Processos para redução de fibrinogênio
BR9306924A (pt) Derivados de 1,3-oxazolidina pirdil-substituídos oidetos de 1,2,4-ditioz lio de novos compostos de partida

Legal Events

Date Code Title Description
TC Change of name
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIDO O PEDIDO COM BASE NOS ARTIGOS 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.